Cargando…

Vibegron shows high selectivity and potent agonist activity for β3-adrenoceptors, irrespective of receptor density

β3-Adrenoceptor (AR) agonists are used to treat patients with an overactive bladder (OAB). Clinical proof-of-concept data have been obtained for the β3-AR agonists vibegron, mirabegron, solabegron, and ritobegron; however, the selectivities of these agents have not been compared directly under the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yamamoto, Shota, Kusabuka, Hotaka, Matsuzawa, Akane, Maruyama, Itaru, Yamazaki, Takanobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473532/ https://www.ncbi.nlm.nih.gov/pubmed/37656760 http://dx.doi.org/10.1371/journal.pone.0290685

Ejemplares similares

Cardiovascular safety of vibegron, a new β3‐adrenoceptor agonist, in older patients with overactive bladder: Post‐hoc analysis of a randomized, placebo‐controlled, double‐blind comparative phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2021)

β(2)‐Adrenoceptor agonist activity of higenamine
por: Hudzik, Thomas J., et al.
Publicado: (2021)

An Evaluation of the Efficacy and Safety of Vibegron in the Treatment of Overactive Bladder
por: Frankel, Jeffrey, et al.
Publicado: (2022)

Selectivity and Maximum Response of Vibegron and Mirabegron for β(3)-Adrenergic Receptors
por: Brucker, Benjamin M., et al.
Publicado: (2022)

Paradoxical bronchoconstriction caused by β(2)-adrenoceptor agonists
por: Ayed, Khadija, et al.
Publicado: (2020)

Budget Impact Analysis of Vibegron for the Treatment of Overactive Bladder in the USA
por: Chen, Jing Voon, et al.
Publicado: (2022)

Structure and Function of an Irreversible Agonist-β(2) Adrenoceptor complex
por: Rosenbaum, Daniel M., et al.
Publicado: (2011)

Functional desensitization of the β(2) adrenoceptor is not dependent on agonist efficacy
por: Rosethorne, Elizabeth M, et al.
Publicado: (2015)

A Selective Pharmacophore Model for β(2)-Adrenoceptor Agonists
por: Xing, Rui-Juan, et al.
Publicado: (2009)

On the Site and Mechanism of Action of β(3)-Adrenoceptor Agonists in the Bladder
por: Andersson, Karl Erik
Publicado: (2017)

Alpha-2 adrenoceptor agonists and sepsis: improved survival?
por: Quintin, Luc
Publicado: (2010)

Long-acting β-adrenoceptor agonists in the management of COPD: focus on indacaterol
por: Beier, Jutta, et al.
Publicado: (2011)

Altered uterine contractility in response to β-adrenoceptor agonists in ovarian cancer
por: Modzelewska, Beata, et al.
Publicado: (2016)

A Clinician’s Perspective on the Mechanism of β(3)-Adrenoceptor Agonists in the Bladder
por: Lee, Tack
Publicado: (2017)

The signaling and selectivity of α‐adrenoceptor agonists for the human α2A, α2B and α2C‐adrenoceptors and comparison with human α1 and β‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2022)

Controversial Effect of Ethanol Irrespective of Kinases Inhibition on the Agonist-Dependant Vasoconstriction
por: Je, Hyun Dong, et al.
Publicado: (2012)

Conformational specificity of opioid receptors is determined by subcellular location irrespective of agonist
por: Crilly, Stephanie E, et al.
Publicado: (2021)

Urodynamic effectiveness of a beta-3 adrenoreceptor agonist (vibegron) for a pediatric patient with anticholinergic-resistant neurogenic detrusor overactivity: a case report
por: Kato, Taiki, et al.
Publicado: (2021)

The long-acting β(2)-adrenoceptor agonist olodaterol attenuates pulmonary inflammation
por: Wex, Eva, et al.
Publicado: (2015)

The selectivity of α‐adrenoceptor agonists for the human α1A, α1B, and α1D‐adrenoceptors
por: Proudman, Richard G. W., et al.
Publicado: (2021)

Interpretation of the Meaningfulness of Symptom Reduction with Vibegron in Patients with Overactive Bladder: Analyses from EMPOWUR
por: Frankel, Jeffrey, et al.
Publicado: (2021)

Reduced suppressive effect of β(2)-adrenoceptor agonist on fibrocyte function in severe asthma
por: Lo, Chun-Yu, et al.
Publicado: (2017)

Fingerprinting heterocellular β-adrenoceptor functional expression in the brain using agonist activity profiles
por: Matt, Rachel A., et al.
Publicado: (2023)

Hinge and Transmembrane Domains of Chimeric Antigen Receptor Regulate Receptor Expression and Signaling Threshold
por: Fujiwara, Kento, et al.
Publicado: (2020)

Structure of the Signal Transduction Domain in Second-Generation CAR Regulates the Input Efficiency of CAR Signals
por: Fujiwara, Kento, et al.
Publicado: (2021)

Beta3-Adrenoceptor Agonists: Possible Role in the Treatment of Overactive Bladder
por: Igawa, Yasuhiko, et al.
Publicado: (2010)

Alpha(2)‐adrenoceptor agonists inhibit form‐deprivation myopia in the chick
por: Carr, Brittany J, et al.
Publicado: (2019)

Efficacy of Vibegron and Mirabegron for Overactive Bladder: A Systematic Literature Review and Indirect Treatment Comparison
por: Kennelly, Michael J., et al.
Publicado: (2021)

Systematic review and meta-analysis of the efficacy and safety of vibegron vs antimuscarinic monotherapy for overactive bladder
por: Su, Shunye, et al.
Publicado: (2021)

Synthesis and in Vitro and in Vivo Characterization of Highly β(1)-Selective β-Adrenoceptor Partial Agonists
por: Mistry, Shailesh N., et al.
Publicado: (2013)

Comparative 3D QSAR study on β(1)-, β(2)-, and β(3)-adrenoceptor agonists
por: Senthil Kumar, P., et al.
Publicado: (2009)

Efficacy of novel β(3)‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 study
por: Yoshida, Masaki, et al.
Publicado: (2018)

Limited β(2)-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics
por: van Veen, Anneke, et al.
Publicado: (2006)

Crystal Structures of a Stabilized β(1)-Adrenoceptor Bound to the Biased Agonists Bucindolol and Carvedilol
por: Warne, Tony, et al.
Publicado: (2012)

Impact of Polymorphic Variants on the Molecular Pharmacology of the Two-Agonist Conformations of the Human β1-Adrenoceptor
por: Baker, Jillian G., et al.
Publicado: (2013)

Rosiglitazone is a superior bronchodilator compared to chloroquine and β-adrenoceptor agonists in mouse lung slices
por: Donovan, Chantal, et al.
Publicado: (2014)

Vibegron for the Treatment of Patients with Dry and Wet Overactive Bladder: A Subgroup Analysis from the EMPOWUR Trial
por: Staskin, David, et al.
Publicado: (2022)

On the improvement of inhibitory response control and visuospatial attention by indirect and direct adrenoceptor agonists
por: Pattij, Tommy, et al.
Publicado: (2011)

Children with ADHD symptoms show deficits in reactive but not proactive inhibition, irrespective of their formal diagnosis
por: van Hulst, Branko M., et al.
Publicado: (2018)

The pharmacological rationale for combining muscarinic receptor antagonists and β-adrenoceptor agonists in the treatment of airway and bladder disease()
por: Dale, Philippa R, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ejfi5tdmlcevu26tsl8efh544c